Journal of Allergy & Therapy

Combat cancer with IgE: Molecular and comparative aspects

7^th International Conference on Allergy, Asthma and Clinical Immunology

September 14-15, 2016 Amsterdam, Netherlands

Josef Singer

Medical University of Vienna, Austria
University Clinic Krems, Austria

Posters & Accepted Abstracts: J Allergy Ther

Abstract:

Immunotherapy of cancer is becoming more and more important in clinical oncology. Especially monoclonal antibodies of the IgG class are commonly used, due to their tumoricidic effects, which have been proven for many indications, together with their good tolerability and safety profile. Recently, also novel antibodies have entered clinical oncology: this engineered IgGs, designed to enhance ADCC are highly successful in clinical trials. The next logical step would be the implementation of other Immunoglobulin classes than IgG. We demonstrated in several studies, that IgE antibodies, specific against tumorassociated antigens are capable to induce apoptosis of tumor cells and can mediate high levels of ADCC. In addition, they are also well tolerated in vivo. Thus, monoclonal IgE antibodies could be valuable options for combating cancer. As the IgE biology of man and mice are highly distinct, novel approaches for further investigations of these antibodies are needed. For this reason, we pursue comparative oncology studies by generating dog monoclonal antibodies in order to establish immunotherapy options also for dog cancer patients. Finally, data from these clinical trials will add valuable information on the full potential of IgE antibodies in clinical oncology.

Biography :

Email: josef.singer@meduniwien.ac.at